Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

NCT ID: NCT03739931

Last Updated: 2025-08-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 134 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-27
• Study Completion Date: 2025-08-01

Brief Summary

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

Detailed Description

This is a Phase 1, open-label, multicenter, dose-escalation study of intratumoral injections of mRNA-2752 alone and in combination with intravenously administered immune checkpoint blockade therapy in participants with histologically confirmed advanced or metastatic solid tumor malignancies or lymphoma. The study consists of Dose Escalation and Dose Confirmation Parts, which will occur in Arm A and Arm B, followed by a Dose Expansion Part, which will occur in Arm B, and a Dose Exploration in Arm C as a neoadjuvant therapy for cutaneous melanoma.

Participants in Arm A and in Arm B will be enrolled into the Dose Escalation Part and the doses of mRNA-2752 will be administered in a dose escalation regimen until a maximum tolerated dose (MTD) or a recommended dose for expansion (RDE) is identified. When the MTD/RDE is identified, participants with solid tumors or lymphoma with visceral lesions may be enrolled into the Dose Confirmation Part to confirm that the dose is also appropriate for this subgroup.

Conditions

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma; Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: mRNA-2752

Participants will be administered mRNA-2752 at an applicable dose as monotherapy.

Group Type: EXPERIMENTAL

mRNA-2752

Intervention Type: BIOLOGICAL

Solution for intratumoral injection

Arm B: mRNA-2752 + Durvalumab

Participants will be administered mRNA-2752 at an applicable dose in combination with durvalumab.

Group Type: EXPERIMENTAL

mRNA-2752

Intervention Type: BIOLOGICAL

Solution for intratumoral injection

Durvalumab

Intervention Type: BIOLOGICAL

Solution for infusion after dilution

Arm C: mRNA-2752 Alone or mRNA-2752 + Durvalumab

Participants will be administered mRNA-2752 at an applicable dose as monotherapy or in combination with durvalumab.

Group Type: EXPERIMENTAL

mRNA-2752

Intervention Type: BIOLOGICAL

Solution for intratumoral injection

Durvalumab

Intervention Type: BIOLOGICAL

Solution for infusion after dilution

Interventions

mRNA-2752

Solution for intratumoral injection

Intervention Type: BIOLOGICAL

Durvalumab

Solution for infusion after dilution

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Written informed consent prior to completing any study-specific procedure
• Histologically confirmed advanced or metastatic disease with at least 1 measurable lesion as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Cheson 2016 criteria
• Dose Escalation/Confirmation:

o Has disease progression after adequate standard of care therapies for metastatic disease that are known to confer clinical benefit, is intolerant to treatment, or refuses standard treatment (no limit to prior lines of therapy)

• Dose Expansion:

• Group 1 Triple negative breast cancer: Must have objective evidence of disease progression during or following at least one prior line of therapy for metastatic or locally advanced disease. Enrollment to Stage 3 of this cohort will include participants who have previously progressed on prior immune checkpoint blockade or participants with programmed death-ligand 1 (PD-L1) negative tumor based on archival tissue (if available).
• Group 2 Head and neck squamous cell carcinoma: Must have objective evidence of disease progression during or following platinum-containing chemotherapy as well as a PD-1/L1 therapy
• Group 3 Non-Hodgkin's lymphoma: Must have objective evidence of disease progression and have received 2 or more prior lines of therapy. Participants with large B-cell lymphoma must have received prior anthracycline containing chemotherapy.
• Group 4 Urothelial cancer, first line: Must be cisplatin ineligible and PD-L1 negative
• Group 5 Urothelial cancer: Must have objective evidence of disease progression during or following platinum-containing chemotherapy
• Group 6 Cutaneous melanoma: Must be refractory to immune checkpoint blockade in the primary or secondary acquired resistance setting.
• Group 7 Non-small cell lung cancer, primary refractory or secondary acquired resistance to immune checkpoint blockade.
• Dose Exploration:

o Newly diagnosed resectable, BRAF wild-type, Stage IIIB/C/D and Stage IV cutaneous melanoma with clinically evident lymph node involvement in the neoadjuvant setting.

• Has a tumor lesion amenable to biopsy and must be willing to provide the baseline and on-treatment tumor biopsy samples if medically feasible. For participants with only 1 lesion amenable to injection, biopsy, and RECIST assessment, that lesion must be ≥2 centimeters (cm)
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤1, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
• Has a body weight of >30 kilograms (kg)
• Adequate hematological and biological function
• Has evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal participants
• Treatment Arm B and Arm C: Clinical euthyroid status. Participants with clinically stable hypothyroidism, on adequate thyroid supplementation, are permitted on study.

Exclusion Criteria

• Has received prior systemic anticancer therapy including investigational agents within 5 half-lives or 28 days of the start of study treatment, whichever is shorter. Participants enrolled to Arm C may not have received any previous anti-cancer therapy, immune therapy, radiotherapy, or investigational agents.
• Has received prior radiotherapy within 14 days before the first dose of study treatment. Participants enrolled to Arm C may not have had prior anticancer therapy including radiotherapy.
• Has received a live vaccine within 30 days before the first dose of study treatment
• Has current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment
• Have major surgical procedures within 28 days or non-study-related minor procedures within 7 days before the first dose of study treatment.
• Requires active systemic anticoagulation at the time of intratumoral injection or biopsy
• Active central nervous system tumors or metastases
• Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and protocol defined laboratory values

• Participants with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Medical Monitor.
• Participants with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Medical Monitor.
• Any active or prior documented autoimmune or inflammatory disorders
• History of primary immunodeficiency, allogenic solid organ transplantation, or tuberculosis
• Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).
• Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (ILD), serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the participant to give written informed consent
• Has active GI bleeding or hemoptysis or history of bleeding disorder
• Is a female participant who is pregnant or breastfeeding or male or female participant of reproductive potential who are not willing to employ effective birth control from screening to 120 days after the last dose of study treatment

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

ModernaTX, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, United States

Providence St. John's Health Center

Santa Monica, California, United States

University of Colorado Denver

Aurora, Colorado, United States

Yale Cancer Center

New Haven, Connecticut, United States

Sarah Cannon Research Institute at Florida Cancer Specialists

Sarasota, Florida, United States

The University of Chicago Medicine

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Cancer Center at Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Henry Ford Hospital

Detroit, Michigan, United States

NYU Langone Medical Center

New York, New York, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

James P. Wilmot Cancer Center

Rochester, New York, United States

The Cleveland Clinic Foundation

Cleveland, Ohio, United States

Oregon Health and Science University

Portland, Oregon, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

One Clinical Research Perth

Nedlands, Western Australia, Australia

Alfred Health

Melbourne, , Australia

Westmead Hospital

Westmead, , Australia

Melanoma Institute of Australia

Wollstonecraft, , Australia

Rambam Medical Center

Haifa, , Israel

Rabin Medical Center

Petah Tikva, , Israel

Chaim Sheba Medical Center

Ramat Gan, , Israel

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Countries

United States; Australia; Israel

References

Srikrishna D, Sachsenmeier K. We need to bring R0 < 1 to treat cancer too. Genome Med. 2021 Jul 26;13(1):120. doi: 10.1186/s13073-021-00940-9.

Reference Type: DERIVED

PMID: 34311780 (View on PubMed)

Other Identifiers

2022-001597-55

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

mRNA-2752-P101

Identifier Type: -

Identifier Source: org_study_id